Biogen Idec, Inc. (NASDAQ:BIIB)
CAPS Rating:
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
0
fsc137
(98.33)
Submitted: 9/18/2006 9:05:59 PM :
Start Price:
$43.50
BIIB Score:
+196.66
Things seem to be looking up after a few hard years, and management is doing its job.
Recs
0
stanhutchings
(< 20)
Submitted: 8/26/2006 12:54:19 AM :
Start Price:
$44.18
BIIB Score:
+189.18
biotech pharma will be higher demand
Recs
0
gliberty
(< 20)
Submitted: 8/22/2006 6:48:46 PM :
Start Price:
$42.68
BIIB Score:
+199.76
Strong future product introductions.
Recs
1
BreakerBeth
(95.00)
Submitted: 5/27/2006 3:17:03 PM :
Start Price:
$46.27
BIIB Score:
+173.66
Looking for good things to happen when Tysabri returns to market.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 81 - 84 of 84 : « Previous 1 2 3 4 5